179 related articles for article (PubMed ID: 24427357)
1. Are synchronous and metachronous bilateral breast cancers different? An immunohistochemical analysis aimed at intrinsic tumor phenotype.
Senkus E; Szade J; Pieczyńska B; Zaczek A; Pikiel J; Sosińska-Mielcarek K; Karpińska A; Jassem J
Int J Clin Exp Pathol; 2014; 7(1):353-63. PubMed ID: 24427357
[TBL] [Abstract][Full Text] [Related]
2. Are synchronous and metachronous bilateral breast cancers different? An immunohistochemical analysis focused on cell cycle regulation.
Senkus E; Szade J; Pieczyńska B; Kunc M; Pliszka A; Jassem J
Histol Histopathol; 2018 Jan; 33(1):55-64. PubMed ID: 28276034
[TBL] [Abstract][Full Text] [Related]
3. Are bilateral breast cancers and breast cancers coexisting with ovarian cancer different from solitary tumors? A pair-matched immunohistochemical analysis aimed at intrinsic tumor phenotype.
Senkus E; Szade J; Pieczyńska B; Zaczek A; Świerblewski M; Biernat W; Jassem J
Pathol Int; 2014 Oct; 64(10):508-17. PubMed ID: 25296577
[TBL] [Abstract][Full Text] [Related]
4. Are bilateral breast cancers different from breast cancers coexisting with ovarian cancer? An immunohistochemical analysis aimed at intrinsic tumor phenotype.
Senkus E; Szade J; Pieczyńska B; Żaczek A; Brożek I; Radecka B; Kowalczyk A; Wełnicka-Jaśkiewicz M; Jassem J
Breast; 2013 Aug; 22(4):425-30. PubMed ID: 23642527
[TBL] [Abstract][Full Text] [Related]
5. Bilateral Breast Cancer After Multimodality Treatment: A Report of Clinical Outcomes in an Asian Population.
Wadasadawala T; Lewis S; Parmar V; Budrukkar A; Gupta S; Nair N; Shet T; Badwe R; Sarin R
Clin Breast Cancer; 2018 Aug; 18(4):e727-e737. PubMed ID: 29254601
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneity in hormone-receptor status and survival outcomes among women with synchronous and metachronous bilateral breast cancers.
Baretta Z; Olopade OI; Huo D
Breast; 2015 Apr; 24(2):131-6. PubMed ID: 25534718
[TBL] [Abstract][Full Text] [Related]
7. Differences in estrogen receptor status, HER2, and p53 comparing metachronous bilateral breast carcinoma.
Matsuo K; Fukutomi T; Tsuda H; Akashi-Tanaka S; Shimizu C; Hasegawa T
J Surg Oncol; 2001 May; 77(1):31-4. PubMed ID: 11344480
[TBL] [Abstract][Full Text] [Related]
8. Bilateral breast carcinoma: risk factors and outcomes for patients with synchronous and metachronous disease.
Heron DE; Komarnicky LT; Hyslop T; Schwartz GF; Mansfield CM
Cancer; 2000 Jun; 88(12):2739-50. PubMed ID: 10870056
[TBL] [Abstract][Full Text] [Related]
9. Receptor characteristics of the second tumor in synchronous versus metachronous breast cancer.
Bu-Ali H; Solh M; Kapur A; Mittal V
Am Surg; 2008 Aug; 74(8):702-5; discussion 706. PubMed ID: 18705570
[TBL] [Abstract][Full Text] [Related]
10. The prognosis of synchronous and metachronous bilateral breast cancer in Chinese patients.
Liang X; Li D; Geng W; Cao X; Xiao C
Tumour Biol; 2013 Apr; 34(2):995-1004. PubMed ID: 23296702
[TBL] [Abstract][Full Text] [Related]
11. Bilateral breast cancer: differential diagnosis using histological and biological parameters.
Gong SJ; Rha SY; Jeung HC; Roh JK; Yang WI; Chung HC
Jpn J Clin Oncol; 2007 Jul; 37(7):487-92. PubMed ID: 17673471
[TBL] [Abstract][Full Text] [Related]
12. Synchronous Metastatic Clear-Cell Renal Cell Carcinoma: A Distinct Morphologic, Immunohistochemical, and Molecular Phenotype.
Kammerer-Jacquet SF; Brunot A; Pladys A; Bouzille G; Dagher J; Medane S; Peyronnet B; Mathieu R; Verhoest G; Bensalah K; Edeline J; Laguerre B; Lespagnol A; Mosser J; Dugay F; Belaud-Rotureau MA; Rioux-Leclercq N
Clin Genitourin Cancer; 2017 Feb; 15(1):e1-e7. PubMed ID: 27444986
[TBL] [Abstract][Full Text] [Related]
13. Oncotype DX in Bilateral Synchronous Primary Invasive Breast Cancer.
Karsten M; Stempel M; Radosa J; Patil S; King TA
Ann Surg Oncol; 2016 Feb; 23(2):471-6. PubMed ID: 26340863
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of synchronous and metachronous bilateral breast cancer.
Kollias J; Ellis IO; Elston CW; Blamey RW
World J Surg; 2001 Sep; 25(9):1117-24. PubMed ID: 11571945
[TBL] [Abstract][Full Text] [Related]
15. Clinical and immunohistochemical features of primary breast cancer and metachronous ovarian and endometrial tumors.
Kryzhanivska AE; Dyakiv IB; Kyshakevych I
Exp Oncol; 2018 Jun; 40(2):124-127. PubMed ID: 29949531
[TBL] [Abstract][Full Text] [Related]
16. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
Liu H; Fan Q; Zhang Z; Li X; Yu H; Meng F
Hum Pathol; 2008 Feb; 39(2):167-74. PubMed ID: 18045647
[TBL] [Abstract][Full Text] [Related]
17. Bilateral synchronous breast cancer developed as metachronous malignancy after therapy of other primaries.
Kurzyński M; Mituś J; Kołodziej-Rzepa M; Sas-Korczyńska B
Ginekol Pol; 2018; 89(5):235-239. PubMed ID: 30084474
[TBL] [Abstract][Full Text] [Related]
18. Prognostic implications of estrogen receptor pattern of both tumors in contralateral breast cancer.
Sandberg ME; Hartman M; Klevebring D; Eloranta S; Ploner A; Hall P; Czene K
Breast Cancer Res Treat; 2012 Jul; 134(2):793-800. PubMed ID: 22622811
[TBL] [Abstract][Full Text] [Related]
19. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
[TBL] [Abstract][Full Text] [Related]
20. The Case to Case Comparison of Hormone Receptors and HER2 Status between Primary Breast Cancer and Synchronous Axillary Lymph Node Metastasis.
Sujarittanakarn S; Himakhun W; Worasawate W; Prasert W
Asian Pac J Cancer Prev; 2020 Jun; 21(6):1559-1565. PubMed ID: 32592349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
